Welcome to our dedicated page for ERPY news (Ticker: ERPY), a resource for investors and traders seeking the latest updates and insights on ERPY stock.
ERP Technologies (ERPY) provides investors and business professionals with essential updates through this comprehensive news hub. Track official announcements including financial disclosures, product enhancements, and strategic collaborations that shape this ERP innovator's market position.
Access timely updates on earnings reports, operational milestones, and partnership developments like ERPY's collaboration with Vetophage. Our curated feed ensures you never miss critical information about software innovations or industry leadership changes.
Discover verified information about enterprise solution developments directly from primary sources. This resource serves both technical professionals seeking product details and investors monitoring organizational growth patterns.
Bookmark this page for streamlined access to ERPY's evolving business narrative. Regular updates ensure you maintain informed perspectives on this dynamic player in enterprise resource planning technology.
ERYTECH and PHERECYDES have proposed a strategic merger aiming to create a global leader in extended phage therapies. This combination will enhance the development of treatments addressing antimicrobial resistance (AMR), focusing on the Phase II PhagoDAIR study and other therapeutic areas with high unmet needs. The merger, expected to close by Q2 2023, anticipates a combined cash runway into Q3 2024, with a consolidated cash position of around €41 million as of December 31, 2022. PHERECYDES shareholders will hold approximately 49% of the combined entity, marking a significant step towards advancing phage therapy initiatives.
The press release dated January 31, 2023, provides monthly updates regarding ERYtech's total number of shares and voting rights. As of January 31, 2023, the total shares stood at 31,018,553, with 32,514,771 gross voting rights and 32,512,271 net voting rights. Comparatively, the figures from December 31, 2022, showed 31,018,553 shares, 32,514,825 gross voting rights, and 32,512,325 net voting rights, indicating slight fluctuations. The company is listed on Euronext Paris and Nasdaq under the symbol ERYP. This report fulfills obligations under French regulations.
The company has reported its monthly update on voting rights and share capital as of December 31, 2022. The total number of shares remains at 31,018,553, with gross voting rights amounting to 32,514,825 and net voting rights at 32,512,325. This data confirms compliance with article 223-16 of the French Autorité des Marchés Financiers regulations. The figures indicate a consistent share structure, essential for investor transparency and confidence.
The monthly report dated October 30, 2022, discloses key shareholder information for Erytech Pharma, listed under symbol ERYP on Euronext Paris and Nasdaq. Total shares of the company stand at 31,018,553, with 32,507,991 gross voting rights and 32,505,491 net voting rights. The report complies with Article 223-16 of the French financial regulatory authority, providing crucial data for investors. This report highlights the company's share structure and voting rights, essential for assessing governance and shareholder influence.
The press release provides monthly information regarding the total number of voting rights and shares for Erytech as of November 30, 2022. The total shares composing the share capital remain steady at 31,018,553. However, the total gross voting rights have slightly decreased to 32,514,528 from the previous month of October, where it was 32,507,991. The net voting rights also showed a small decline to 32,512,028. This information reflects ongoing stability in share capital but a minor reduction in voting rights.
ERYTECH Pharma announced it received a notice from Nasdaq indicating that its American Depositary Shares (ADSs) no longer comply with the minimum bid price requirement due to a closing bid price below $1.00 for 30 consecutive business days. The notification, dated October 7, 2022, does not immediately affect the listing, which will continue under the symbol ERYP.
The company has a 180-day grace period until April 5, 2023, to regain compliance by achieving a closing bid price of $1.00 for ten consecutive days.
Summary of Voting Rights and Shares as of September 30, 2022
As of September 30, 2022, Erytech Pharma reported a total of 31,018,553 shares in its share capital, with 32,507,992 gross voting rights and 32,505,492 net voting rights. This indicates a slight decrease in voting rights from the previous month, where the gross voting rights stood at 32,508,024 and net voting rights at 32,505,524. The company's shares are traded on Euronext Paris and Nasdaq under the symbol ERYP.
ERYTECH Pharma (ticker: ERYP) provided a business and financial update for the first half of 2022. The company sold its U.S. cell therapy manufacturing facility to Catalent for $44.5 million, significantly improving its cash position, which reached €53.3 million ($55.8 million) by June 30, 2022. However, ERYTECH halted its Biologics License Application (BLA) submission for Graspa in hypersensitive acute lymphoblastic leukemia due to new FDA data requests. The company is prioritizing strategic partnerships and focusing on promising preclinical programs, with updates expected in Q4 2022.
This press release provides monthly updates on the total number of voting rights and shares as of August 31, 2022. The report states a total of 31,018,553 shares comprising the share capital, with gross voting rights reported at 32,508,024 and net voting rights at 32,505,524. These figures reflect the company's compliance with Article 223-16 of the French Autorité des Marchés Financiers regulations. The document is part of Erytech's ongoing commitment to transparency for shareholders and is available on their official website.
Voting Rights Update: As of July 31, 2022, Erytech Pharma reported a total of 31,018,553 shares in its capital. The gross voting rights stood at 32,521,126, while net voting rights were recorded at 32,518,626. This data is crucial as it provides insights into shareholder voting power and potential influence on company decisions. The figures reflect a stable share count with consistent voting rights, ensuring transparency in governance.
